rotaviru
infect
emerg
import
caus
complic
organ
transplant
recipi
might
play
role
pathogenesi
inflammatori
bowel
diseas
ibd
wide
use
immunosuppress
drug
organ
recipi
treatment
ibd
clinic
studi
aim
investig
effect
modeofact
rotaviru
replic
human
intestin
cell
line
model
human
primari
intestin
organoid
laboratori
rotaviru
strain
patientderiv
rotaviru
isol
use
demonstr
significantli
inhibit
rotaviru
replic
intestin
epithelium
model
importantli
gene
knockdown
knockout
cellular
target
significantli
inhibit
rotaviru
replic
indic
support
role
rotaviru
infect
demonstr
effect
inhibit
activ
form
essenti
mediat
antirotaviru
effect
consist
ectop
overexpress
facilit
inact
specif
inhibitor
inhibit
rotaviru
replic
conclus
identifi
effect
inhibitor
rotaviru
replic
via
inhibit
activ
thu
transplant
patient
ibd
patient
infect
rotaviru
risk
rotaviru
infect
choic
treatment
appear
ration
rotaviru
doubl
strand
rna
dsrna
viru
reovirida
famili
major
caus
gastroenter
particularli
children
younger
year
age
major
global
health
problem
viru
caus
million
diarrhea
episod
million
hospit
estim
death
worldwid
annual
grimwood
butteri
tate
et
al
although
rotaviru
infect
mainli
occur
develop
countri
also
result
death
hospit
admiss
infant
european
union
vesikari
et
al
besid
young
children
organ
transplant
patient
also
suscept
rotaviru
infect
irrespect
age
caus
longterm
diarrhea
even
death
due
graft
failur
yin
et
al
although
two
global
licens
rotaviru
vaccin
launch
specif
antivir
treatment
avail
thio
analogu
natur
occur
purin
base
guanin
use
clinic
sinc
earli
munshi
et
al
initi
develop
treat
cancer
wherea
current
wide
use
immunosuppress
agent
organ
transplant
also
use
treatment
acut
lymphoblast
leukemia
children
autoimmun
diseas
bourgin
et
al
particular
often
use
treat
inflammatori
bowel
diseas
ibd
de
boer
et
al
ibd
includ
crohn
diseas
cd
ulcer
coliti
uc
indetermin
coliti
ic
repres
heavi
burden
western
countri
kolho
et
al
although
caus
exacerb
ibd
remain
poorli
character
gastrointestin
infect
includ
rotaviru
might
induc
flare
ibd
mascle
et
al
thu
prevent
treat
rotaviru
infect
patient
import
upon
ingest
first
metabol
dosedepend
manner
n
mean
sem
p
p
mannwhitney
test
au
denot
artifici
unit
b
effect
product
infecti
viral
particl
determin
method
bar
repres
tcid
ml
mean
sem
n
p
mannwhitney
test
c
treatment
h
significantli
inhibit
viral
protein
rotaviru
infect
cell
dosedepend
manner
densitometr
analysi
immunoreact
ban
western
bot
quantifi
imagej
softwar
ratio
express
arbitrari
unit
monophosph
subsequ
diphosph
final
triphosph
chouchana
et
al
among
metabolit
abl
compet
endogen
guanosin
phosphat
bind
form
complex
complex
turn
incap
support
format
activ
fig
high
barrier
drug
resist
develop
rotaviru
serial
passag
cell
expos
control
increas
concentr
passag
infect
cultur
expos
ngml
passag
wherea
drug
concentr
increas
ngml
subsequ
later
passag
effect
ngml
passag
drug
treat
untreat
rotaviru
quantifi
use
qrtpcr
retain
antirotaviru
activ
even
continu
exposur
passag
cell
cell
b
configur
process
interact
gtp
thu
indirectli
provok
inhibit
signal
shin
et
al
substanti
consequ
cellular
physiolog
member
ra
superfamili
rho
gtpase
gtpbound
mediat
myriad
cellular
process
includ
actin
reorgan
gene
transcript
intriguingli
ibd
character
hyperactiv
phagocyt
compart
associ
reduc
effector
function
sensit
treatment
parikh
et
al
inhibit
result
treatment
restor
innat
immun
function
phagocyt
ibd
patient
contribut
diseas
remiss
parikh
et
al
thu
hyperactiv
appear
import
immunosuppress
effector
human
pathophysiolog
least
phagocyt
compart
given
clinic
relev
potenti
reveal
mechanist
insight
investig
effect
mechanismofact
rotaviru
replic
end
demonstr
effect
combat
rotaviru
replic
inhibit
activ
simian
rotaviru
strain
patientderiv
rotaviru
isol
prepar
previous
describ
yin
et
al
yin
et
al
stock
mgml
sigmaaldrich
dissolv
alkali
solut
naoh
mgml
merck
millipor
dissolv
h
mm
chemic
store
aliquot
frozen
human
colon
cancer
cell
line
human
embryon
kidney
cell
line
hek
cell
grown
dulbecco
modifi
eagl
medium
dmem
invitrogengibco
breda
netherland
supplement
volvol
heatinactiv
fetal
calv
serum
fc
hyclon
lonan
utah
penicillin
iuml
streptomycin
mgml
invitrogengibco
humidifi
incub
knockout
mous
embryon
fibroblast
mef
cell
cultur
dmem
supplement
fc
penicillin
iu
ml
streptomycin
mgml
lglutamin
gibco
life
technolog
nonessenti
amino
acid
gibco
life
technolog
sodiumpyruv
gibco
life
technolog
cell
stabl
knockdown
gener
transduct
lentivir
shrna
produc
cell
target
select
puromycin
describ
previous
yin
et
al
shrna
target
sequenc
use
studi
list
tabl
cultur
human
intestin
organoid
perform
previous
describ
yin
et
al
inocul
treatment
cell
human
intestin
organoid
patientderiv
rotaviru
perform
previous
describ
yin
et
al
viabil
cell
organoid
determin
bromid
mtt
assay
briefli
cell
cellswel
organoid
seed
cultur
plate
incub
variou
concentr
h
follow
ad
mtt
solut
well
incub
h
subsequ
medium
remov
replac
dmso
incub
min
absorb
measur
nm
enzymelink
immunosorb
assay
reader
biorad
effect
ribavirin
host
cell
viabil
determin
mtt
assay
fig
constitut
activ
domin
inact
plasmid
prepar
previous
describ
apolloni
et
al
hek
cell
seed
plate
rac
activ
assay
plate
infect
assay
confluenc
cell
wash
pb
follow
ad
optimem
reduc
serum
medium
plasmid
polyethylenimin
pei
per
well
plate
optimem
reduc
serum
medium
thermo
fisher
scientif
plasmid
polyethylenimin
pei
sigmaaldrich
per
well
plate
h
incub
ml
ml
dmem
contain
fc
ad
well
plate
plate
respect
transfect
cell
infect
rotaviru
h
total
cellular
rna
isol
use
nucleospin
rna
kit
machereynagel
germani
follow
manufactur
protocol
quantifi
nanodrop
wilmington
de
usa
cdna
synthes
use
revers
transcript
system
takara
accord
manufactur
instruct
takara
bio
inc
result
cdna
dilut
dilut
cdna
use
qrtpcr
primer
list
tabl
qrtpcr
experi
perform
sybrgreenbas
appli
biosystem
sybr
green
pcr
master
mix
thermo
fisher
scientif
life
scienc
realtim
pcr
steponeplu
system
thermo
fisher
scientif
life
scienc
express
target
mrna
normal
glyceraldehyd
dehydrogenas
gapdh
mrna
gene
express
analysi
perform
method
yin
et
al
yin
et
al
level
gtp
detect
use
rac
interact
bind
crib
domain
pak
describ
previous
fuhler
et
al
brief
gstpakcrib
protein
precoupl
glutathionesepharos
bead
sigmaaldrich
min
cell
treat
variou
concentr
h
seed
lyse
min
lysi
buffer
mm
tri
ph
glycerol
mm
nacl
mm
mgcl
mm
sodium
orthovanad
proteas
inhibitor
cell
lysat
incub
precoupl
bead
min
agaros
bead
wash
time
lysi
buffer
follow
boil
laemmli
buffer
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
analysi
cell
lysat
subject
sdspage
protein
transfer
pvdf
membran
immobilonfl
monoclon
antibodi
rabbit
cell
signal
rotaviru
mous
monoclon
antibodi
provid
professor
harri
greenberg
stanford
univers
school
medicin
usa
detect
western
blot
analysi
detect
serv
load
control
mous
monoclon
santa
cruz
previous
describ
versteeg
et
al
investig
whether
rotaviru
develop
resist
treatment
virus
passag
cell
absenc
drug
vehicl
control
presenc
gradual
increas
concentr
drug
ngml
passag
ngml
passag
brief
cell
plate
inocul
viru
moi
h
follow
ad
without
drug
control
h
cell
supernat
harvest
subsequ
frozen
thaw
centrifug
supernat
contain
passag
virus
store
use
next
passag
virus
serial
passag
use
aliquot
viral
stock
preced
passag
infect
fresh
cell
effect
passag
viru
titer
quantifi
qrtpcr
caption
next
page
yin
et
al
antivir
research
data
present
mean
statist
comparison
differ
group
perform
mannwhitney
test
twotail
use
graphpad
prism
error
bar
repres
sem
p
valu
consid
statist
signific
assess
effect
rotaviru
replic
treat
rotavirusinfect
cell
variou
concentr
ngml
h
result
dosedepend
inhibit
rotaviru
rna
replic
fig
n
p
p
ic
valu
rotaviru
substanti
concentr
reach
patient
undergo
azathioprin
therapi
cc
cell
select
index
si
cc
ic
tabl
confirm
infecti
viru
product
level
protein
level
rotaviru
protein
fig
c
verifi
effect
rotaviru
replic
rotavirusinfect
cell
treat
differ
time
point
h
demonstr
significantli
inhibit
rotaviru
rna
replic
timedepend
manner
fig
n
p
p
result
substanti
experi
human
primari
intestin
organoid
model
system
recapitul
mani
aspect
intestin
epithelium
includ
presenc
villu
domain
crypt
domain
fig
sato
clever
significantli
inhibit
rotaviru
replic
viru
product
organoid
fig
g
n
p
p
result
essenti
repeat
use
five
patientderiv
rotaviru
isol
cell
also
human
intestin
organoid
tabl
treatment
ngml
inhibit
patientderiv
isol
cell
fig
human
intestin
organoid
fig
henc
significantli
counteract
rotaviru
replic
clinic
relev
concentr
rotaviru
serial
passag
presenc
escal
concentr
assess
potenti
drug
resist
develop
control
wildtyp
rotaviru
passag
absenc
drug
initi
ten
passag
infect
cultur
expos
ngml
wherea
drug
concentr
increas
ngml
subsequ
later
passag
passag
effect
ngml
repres
passag
drug
treat
untreat
rotaviru
quantifi
qrtpcr
result
indic
rotaviru
remain
sensit
treatment
cell
fig
cell
fig
therefor
rotaviru
easili
develop
resist
suggest
antivir
effect
like
depend
cellular
target
direct
interact
viru
although
initi
character
nucleotid
synthesi
inhibitor
last
decad
becom
clear
mani
effect
least
gastrointestin
pathophysiolog
depend
potenc
inhibit
shin
et
al
thu
investig
potenti
role
rotaviru
replic
end
perform
lentivir
rnaimedi
lossoffunct
assay
silenc
gene
two
five
rnai
vector
show
potent
knockdown
target
gene
fig
importantli
two
rnai
vector
result
n
p
n
p
reduct
rotaviru
viral
rna
respect
fig
appar
agreement
obtain
knockout
mous
embryon
fibroblast
cell
mef
statu
bona
fide
knockout
confirm
western
blot
assay
fig
rotaviru
replic
knockout
mef
significantli
less
effici
n
p
compar
replic
wild
type
mef
lflf
fig
thu
decreas
level
correl
increas
resist
toward
rotaviru
replic
act
binari
switch
cellular
biochemistri
capabl
provok
signal
activ
gtpbound
form
shin
et
al
specif
inhibitor
abl
effect
inhibit
accumul
cell
evid
test
specif
pulldown
assay
fig
b
importantli
treatment
either
h
result
n
p
n
p
reduct
viral
rna
level
respect
fig
ic
valu
rotaviru
cc
cell
si
tabl
inhibitori
effect
rotaviru
infecti
verifi
western
blot
assay
reveal
treatment
either
significantli
inhibit
rotaviru
protein
synthesi
cell
fig
effect
drug
confirm
experi
human
primari
intestin
organoid
indic
n
p
reduct
viral
rna
organoid
fig
follow
treatment
next
test
effect
constitut
activ
domin
neg
form
rotaviru
replic
done
transfect
activ
plasmid
domin
neg
plasmid
express
plasmid
success
test
flow
cytometri
fig
accordingli
cell
display
abund
contrast
low
cell
determin
rac
pulldown
assay
fig
result
confirm
analyz
abund
statu
fig
importantli
promot
inhibit
rotaviru
replic
fig
taken
togeth
activ
support
rotaviru
replic
fig
effect
combin
ribavirin
rotaviru
replic
treatment
h
significantli
inhibit
viral
genom
rna
rotaviru
infect
cell
dosedepend
manner
n
mean
sem
p
mannwhitney
test
b
treatment
h
remark
inhibit
viral
protein
rotaviru
infect
cell
dosedepend
manner
ratio
express
arbitrari
unit
c
effect
combin
variou
concentr
rotaviru
replic
cell
synergi
plot
repres
percentag
antivir
activ
abovebelow
expect
activ
combin
base
data
shown
c
e
treatment
ribavirin
h
significantli
inhibit
viral
genom
rna
rotaviru
infect
cell
dosedepend
manner
n
mean
sem
p
p
mannwhitney
test
f
treatment
ribavirin
h
remark
inhibit
viral
protein
rotaviru
infect
cell
dosedepend
manner
ratio
express
arbitrari
unit
g
effect
combin
variou
concentr
ribavirin
rotaviru
replic
cell
h
synergi
plot
repres
percentag
antivir
activ
abovebelow
expect
activ
combin
base
data
shown
g
inhibit
rotaviru
via
suppress
gdpgtp
cycl
inhibit
activ
report
mani
cell
type
fuhler
et
al
shin
et
al
tied
et
al
employ
pulldown
assay
fig
observ
potent
inhibit
accumul
wherea
correspond
western
blot
show
reduc
overal
level
cell
follow
treatment
fig
function
studi
use
knockdown
cell
fig
c
perform
demonstr
requir
combat
rotaviru
replic
agreement
pharmacolog
inhibitor
inhibit
rotaviru
replic
knockout
mef
cell
fig
thu
inhibit
rotaviru
via
suppress
activ
combin
effect
moder
antagonist
effect
ribavirin
rotaviru
replic
interferonalpha
ribavirin
wide
use
gener
antivir
confirm
significantli
inhibit
rotaviru
replic
vitro
yin
et
al
consist
demonstr
inhibitori
effect
ribavirin
rotaviru
rna
fig
viral
protein
fig
f
dosedepend
manner
ic
valu
rotaviru
iu
cc
cell
iu
si
tabl
ic
valu
ribavirin
rotaviru
cc
ribavirin
cell
si
tabl
next
assess
combinatori
antivir
effect
ribavirin
combin
result
combin
synergi
antagon
antivir
effect
synergi
volum
fig
howev
combin
ribavirin
result
moder
antagonist
antivir
effect
synergi
volum
fig
h
studi
demonstr
effect
inhibit
rotaviru
replic
via
inhibit
activ
particularli
interest
view
rotaviru
replic
especi
issu
organ
transplant
recipi
patient
ibd
therapeut
option
group
patient
base
find
present
current
studi
choic
patient
appear
ration
particular
risk
rotaviru
infect
yin
et
al
result
fit
well
momentum
studi
document
antivir
activ
instanc
report
combat
middl
east
respiratori
syndrom
coronaviru
infect
augment
interferon
respons
cheng
et
al
also
report
simian
viru
dna
replic
antagon
maybaum
et
al
interestingli
report
vaccin
ibd
patient
lower
titer
hepat
b
surfac
antibodi
hbsab
might
influenc
use
immunosuppress
includ
watt
et
al
prodrug
convert
pharmacolog
activ
phosphat
also
call
nucleotid
phosphat
bind
form
complex
inactiv
shin
et
al
major
player
rho
famili
small
gtpase
play
vital
role
variou
cellular
signal
pathway
regul
wide
varieti
cell
function
includ
gene
transcript
cell
prolifer
apoptosi
motil
redox
signal
dambrosi
et
al
express
ubiquit
two
conform
state
includ
inact
gdpbound
form
activ
gtpbound
form
bosco
et
al
exert
biolog
function
mainli
activ
ie
gtpbound
form
bosco
et
al
mani
virus
interfer
employ
conform
state
regul
infect
earli
stage
african
swine
fever
viru
asfv
infect
activ
inhibit
abl
suppress
product
viru
quetgla
et
al
found
activ
intracellular
matur
viru
mv
vaccinia
viru
entri
mercer
heleniu
although
rotaviru
replic
per
se
affect
activ
fig
demonstr
lossoffunct
gene
knockdown
knockout
significantli
impair
rotaviru
replic
line
previou
find
knockdown
could
significantli
inhibit
enteroviru
infect
karjalainen
et
al
specif
activ
requir
shown
oppos
effect
ectop
overexpress
activ
inact
form
rotaviru
replic
mechanist
explain
potent
antirotaviru
effect
inhibitor
note
shown
inhibit
replic
sever
influenza
virus
includ
human
viru
strain
pandem
highli
pathogen
avian
viru
strain
dierk
et
al
despit
absenc
approv
medic
treat
rotaviru
wide
use
gener
antivir
includ
ribavirin
studi
rotaviru
experiment
model
yin
et
al
evalu
combinatori
effect
ribavirin
consist
confirm
ribavirin
inhibit
rotaviru
replic
rna
protein
level
fig
b
found
increas
potenc
presenc
howev
whether
combin
could
use
treat
rotaviru
infect
patient
remain
investig
conclus
studi
demonstr
effect
inhibit
rotaviru
replic
high
barrier
drug
resist
develop
identifi
activ
form
import
host
factor
support
rotaviru
replic
exert
antirotaviru
effect
via
specif
inhibit
activ
herein
studi
provid
import
refer
clinician
optim
medic
organ
recipi
ibd
patient
infect
rotaviru
risk
rotaviru
replic
result
may
also
help
develop
new
antirotaviru
therapi
author
declar
conflict
interest
yy
sc
mh
ww
lx
wd
cq
js
perform
experi
gf
av
contribut
scientif
discuss
facil
yy
mp
qp
conceiv
project
wrote
manuscript
